• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Introduction to 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride (CAS No. 103039-94-7) in Modern Chemical and Biomedical Research

3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride, identified by its Chemical Abstracts Service (CAS) number 103039-94-7, is a compound of significant interest in the fields of pharmaceutical chemistry and biomedical research. This compound belongs to a class of molecules characterized by a piperidine moiety, which is a six-membered heterocyclic amine containing one nitrogen atom. The presence of the 1-methyl-4-piperidinyl substituent and the carboxylic acid functionality, further enhanced by its hydrochloride salt form, imparts unique physicochemical properties that make it a valuable scaffold for drug discovery and development.

The hydrochloride salt form of this compound enhances its solubility in aqueous media, a critical factor for pharmaceutical applications where bioavailability and formulation stability are paramount. The carboxylic acid group provides a site for further chemical modification, enabling the synthesis of more complex derivatives with tailored biological activities. This flexibility has positioned 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride as a versatile intermediate in the synthesis of novel therapeutic agents.

In recent years, there has been growing interest in piperidine-containing compounds due to their demonstrated efficacy in modulating various biological pathways. Piperidine derivatives have been extensively explored as pharmacophores in the development of drugs targeting neurological disorders, cardiovascular diseases, and infectious diseases. The structural motif of 1-methyl-4-piperidinyl is particularly noteworthy, as it has been shown to enhance metabolic stability and binding affinity to biological targets. For instance, modifications at the piperidine ring have been associated with improved pharmacokinetic profiles, reducing the need for frequent dosing and minimizing side effects.

Recent studies have highlighted the potential of 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride in the development of small-molecule inhibitors targeting enzymes involved in cancer metabolism. Specifically, researchers have investigated its utility as a precursor in the synthesis of compounds that inhibit poly(ADP-ribose) polymerases (PARPs), which play a crucial role in DNA repair and cell survival. Inhibiting PARP enzymes has emerged as a promising strategy in treating certain cancers, particularly those with defects in DNA repair pathways, such as BRCA-mutated ovarian and breast cancers. The carboxylic acid moiety in 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride allows for derivatization into potent PARP inhibitors with improved selectivity and potency.

Moreover, the hydrochloride salt form of this compound has been utilized in preclinical studies to assess its potential as an anti-inflammatory agent. Piperidine derivatives have demonstrated anti-inflammatory properties by modulating cytokine production and inhibiting inflammatory signaling pathways. The structural features of 1-methyl-4-piperidinyl contribute to its ability to interact with key inflammatory mediators, making it a promising candidate for treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Further research is ongoing to elucidate the molecular mechanisms underlying its therapeutic effects.

The synthesis of 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride involves multi-step organic transformations that highlight its synthetic versatility. Key steps include nucleophilic substitution reactions to introduce the piperidine ring followed by functional group transformations to incorporate the carboxylic acid group. The final step involves conversion to the hydrochloride salt to enhance solubility and stability. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making this compound more accessible for industrial applications.

In conclusion, 3-(1-methyl-4-piperidinyl)propanoic acid hydrochloride (CAS No. 103039-94-7) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and broad range of potential applications. Its role as a key intermediate in drug development underscores its importance in modern biomedical research. As our understanding of disease mechanisms continues to evolve, compounds like this will remain at the forefront of therapeutic innovation, offering new hope for patients worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)